Stefan Bernstein explains how the EU/Greenland critical raw materials partnership benefits GreenRoc. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Regulatory News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 10.75
Bid: 10.50
Ask: 11.00
Change: -3.75 (-25.86%)
Spread: 0.50 (4.762%)
Open: 12.00
High: 11.00
Low: 10.75
Prev. Close: 14.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on SRA737 Licensing Agreement

12 Nov 2020 12:13

RNS Number : 1505F
Sareum Holdings PLC
12 November 2020
 

SAREUM HOLDINGS PLC

("Sareum" or "the Company")

Sareum Provides Update on Licensing Agreement Regarding SRA737, a Chk1 inhibitor in Clinical Development Targeting Solid Cancers

Amended agreement expected to clear path to advancing clinical development of SRA737

Cambridge, UK, 12 November 2020 - Sareum Holdings plc (AIM: SAR), the specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases, announces that amended terms (the "Amendment") to the 2016 licensing agreement between Sierra Oncology, Inc. ("Sierra") and CRT Pioneer Fund LP ("CPF") for the Chk1 inhibitor SRA737 (the "CRT License Agreement") have been agreed between the two parties.

Details of the Amendment have been published in Sierra's Form 8-K, filed with the US Securities and Exchange Commission (SEC) today, and are set out below.

Overview of SRA737

SRA737 is a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK.

SRA737 was licensed by CPF to Sierra in September 2016 for up to $328.5 million in developmental, regulatory and commercial milestones, plus royalties on the net sales of any product successfully developed. Sareum was eligible to receive 27.5% of the economics equating to up to $88 million in milestone payments, plus sales royalties, as SRA737 advances.

Details of the CRT License Agreement and the Amendment

Pursuant to the CRT License Agreement, Sierra made a one-time upfront payment of $7.0 million to CPF in October 2016 and paid $2.0 million to CPF in January 2017 for the successful transfer of two ongoing Phase 1 clinical trials. Sareum received a total of approximately $2.5 million from these payments.

Under the terms of the original CRT License Agreement, additional milestone payments of up to an aggregate of $319.5 million were payable to CPF upon the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $7.5 million upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the United States, and a payment of $12.0 million upon the dosing of the first patient of a randomised Phase 2 trial of SRA737.

Pursuant to the terms of the Amendment, Sierra and CPF have agreed to a decrease in the additional milestone payments of up to an aggregate of $290.0 million that may be payable to CPF upon the achievement of certain developmental, regulatory and commercial milestones, including a milestone payment of $2.0 million upon the dosing of the first patient of the first trial of SRA737 following the Amendment.

In the event that the milestone payment for a milestone event, as defined in the CRT License Agreement, becomes due, but no milestone payment for an earlier milestone event has been paid, then the milestone payment attached to the earlier milestone event will automatically become due and payable contemporaneously with the payment for the later milestone event. Sierra will accrue for any future milestones payments once they are considered probable of occurring.

In addition, Sierra remains required to pay CPF, on a product-by-product and country-by-country basis, tiered high single-digit to low double-digit royalties on the net sales of any product successfully developed.

Sareum continues to be eligible for 27.5% of the economics of the CRT License Agreement, as amended.

Sareum's CEO, Dr Tim Mitchell, commented:

"We believe this revised agreement between Sierra and CPF clears the way for the further clinical development of SRA737, either internally or through a partner, giving Sareum the potential to benefit from downstream milestone payments.

"While the aggregate level of these milestone payments is reduced, we are confident that this amendment will expedite the advancement of the SRA737 programme in a timely manner. We look forward to further updates on the clinical development of SRA737, a molecule that has shown great promise in clinical trials and preclinical studies, particularly in combination with other types of cancer therapy.

"In parallel, we continue to invest our own cash resources to progress our exciting wholly owned TYK2/JAK1 inhibitor programmes towards the clinic as planned."

This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014.

For further information, please contact:

Sareum Holdings plc

Tim Mitchell, CEO

 

 

01223 497 700

Strand Hanson Limited (Nominated Adviser)

James Dance / Richard Tulloch

 

 

020 7409 3494

Hybridan LLP (Nominated Broker)

Claire Noyce / John Beresford-Peirse

 

 

020 3764 2341

Citigate Dewe Rogerson (Financial PR)

Mark Swallow/ David Dible

 

020 7638 9571

 

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.

Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the 'cytokine storm' immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).

The Company's preclinical FLT3+Aurora inhibitor programme targeting haematological cancers is licensed to a China-based specialty pharma company.

Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms. Preliminary Phase 2 and comprehensive preclinical data suggest SRA737 may have broad application in combination with other oncology and immune-oncology drugs in genetically defined patients.

SRA737 was discovered and initially developed by scientists at The Institute of Cancer Research in collaboration with Sareum, and with funding from Sareum and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra continues to explore options that would enable the development of SRA737 to advance.

Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGRLLLFFBFLFFBF
Date   Source Headline
28th Mar 20247:02 amRNSWRAP Retail Offer
28th Mar 20247:01 amRNSEquity Fundraise
28th Mar 20247:00 amRNSSareum Half-Year Report
15th Mar 20247:00 amRNSNew Patent Allowance
12th Mar 20241:30 pmRNSNotice of Interim Results and Trading Update
15th Feb 20247:00 amRNSUpdate on SDC-1801 Clinical Trial Progress
2nd Jan 20247:00 amRNSDevelopment and commercialisation licence SRA737
14th Dec 20233:35 pmRNSResults of AGM
14th Dec 20237:00 amRNSAnnual General Meeting Statement
23rd Nov 20237:00 amRNSDrawdown of Equity Prepayment Facility
21st Nov 20237:00 amRNSNotice of AGM, Annual Report and Accounts
9th Nov 20237:00 amRNSInitiation of food effects study for SDC-1801
8th Nov 20233:03 pmRNSDirector Dealings
3rd Nov 20237:05 amRNSSareum enhances SDC-1801 patent protection
2nd Nov 20232:48 pmRNSExercise of Share Options and Director Dealings
9th Oct 20237:00 amRNSFinal Results for the Year Ended 30 June 2023
3rd Oct 20237:00 amRNSNotice of Results and Investor Presentation
6th Sep 20237:00 amRNSDirector's Dealing
5th Sep 20237:00 amRNSDirector Dealing
4th Sep 20237:00 amRNSDosing of first subjects in MAD Phase 1a trial
16th Aug 20237:00 amRNSUpdate on financial and operational progress
3rd Aug 20237:00 amRNSEquity Prepayment Facility of up to £5 million
26th Jun 20237:00 amRNSSareum Announces Two New Granted Patents
6th Jun 20237:00 amRNSDosing commences in Phase 1a trial of SDC-801
18th May 20237:00 amRNSPhase 1a clinical trial for SDC-1801
5th May 20239:20 amRNSApproval to initiate Phase 1 clinical trial
22nd Mar 20237:00 amRNSHalf-Year Report
15th Mar 20237:01 amRNSUpdate on SDC-1801
15th Mar 20237:00 amRNSNotice of Half-Year Results
6th Mar 20237:00 amRNSUpdate on SRA737
29th Dec 20223:14 pmRNSDirector/PDMR Shareholding
16th Dec 20223:29 pmRNSResults of AGM
16th Dec 20227:00 amRNSAGM Statement
24th Nov 20227:00 amRNSNotice of AGM, Annual Report and Accounts
21st Nov 20227:00 amRNSSareum notes publication of SRA737 clinical data
9th Nov 20224:41 pmRNSSecond Price Monitoring Extn
9th Nov 20224:35 pmRNSPrice Monitoring Extension
9th Nov 20222:05 pmRNSSecond Price Monitoring Extn
9th Nov 20222:00 pmRNSPrice Monitoring Extension
9th Nov 202211:05 amRNSSecond Price Monitoring Extn
9th Nov 202211:00 amRNSPrice Monitoring Extension
9th Nov 20229:05 amRNSSecond Price Monitoring Extn
9th Nov 20229:00 amRNSPrice Monitoring Extension
8th Nov 20225:23 pmRNSUpdate on SDC-1801 CTA Application
24th Oct 20227:00 amRNSFinal Results for the Year Ended 30 June 2022
12th Oct 20227:00 amRNSUpdate on SRA737
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn
30th Sep 20224:36 pmRNSPrice Monitoring Extension
12th Sep 20227:00 amRNSSareum notes FDA approval of first TYK2 Inhibitor
28th Jul 20227:00 amRNSCTA application to MHRA and Corporate Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.